about
Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparinNSAIDs and heart failureTenecteplase: new preparation. Another thrombolytic agent for myocardial infarction: a slightly simpler treatmentCardiovascular adverse effects of coxibsCelecoxib: new indication. Colorectal cancer: no preventive benefitHuman protein C: new preparations. Effective replacement therapy for some clotting disordersAnagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatmentClopidogrel: new indication. In combination with aspirin: marginal additional benefitsTreatment of ductal carcinoma in situ: an uncertain harm-benefit balanceNalmefene. Alcohol dependence: no advanceBosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusionHIV exposure through contact with body fluidsGallstones containing dipyridamoleHypotension and coronary events on nifedipine: reassessing nifedipine safetyInsulin use: preventable errors.Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.Stable angina: role of ivabradine unchanged between 2006 and 2010.Andrew Herxheimer: his life's work, to be continued.Stop DSM!Medical students' and junior doctors' attitudes to drug companies: a survey conducted in Lyon University Hospital, France.Who funds patient groups?SSRI antidepressants and birth defectsAtovaquone + proguanil: new preparation. Second-line antimalarial combinationArtesunate. The standard intravenous treatment for severe attacks of malariaMefloquine: persistent vestibular disordersArtenimol + piperaquine. Very slow piperaquine elimination: cardiovascular risks and interactionsInformed screeningSevere malaria: artesunate is now the standard treatmentScreening: tell the truthBedaquiline. More data needed on this dangerous antitubercular drugAdverse effects of papillomavirus vaccines: pharmacovigilance data in 2008Pegylated interferon: new preparation. Chronic hepatitis C: advantageous for some patients, but more data neededIpilimumab. Immunostimulant; more assessment neededEmtricitabine + tenofovir to prevent HIV transmission. More evaluation neededPrevention of mother-child HIV transmission: progress and problemsAntiviral drugs in influenza: an adjunct to vaccination in some situationsTowards better patient care: drugs to avoidHepatitis B vaccination in countries with low endemicityMammographic screening for breast cancer. Overdiagnosis: an insidious adverse effect of screeningMammographic breast cancer screening. Part II. Non-randomised comparisons: results similar to those of randomised trials
P1433
Q28188192-81750D56-859D-41B5-BB6C-CACB1F717279Q28192284-758AD886-B678-4011-A749-226A0A18A3A5Q28193222-AE4AC352-218B-4902-A153-D6AF27DE637BQ28194405-748284E3-636F-44C2-BFBE-2AE2F9D3A0F6Q28195820-5B615F57-3628-4289-84D2-349421368327Q28211683-67295374-25E7-4E48-9266-62BE7AA0EDEBQ28218934-9DF64861-1289-41EB-BCC6-66E5207C6BA2Q28220347-907CE629-412D-4A58-91E9-699F904ECB51Q28235376-78042233-7129-4405-81E1-B5583CCB2E29Q28245896-BE11B820-9578-4655-8B8A-B8F5168F4A7CQ28248708-F8773921-458D-4146-8A9E-DE4CBF6FB21AQ28264833-969B08D5-5012-482C-B1B4-78DED4E4FBA7Q28376262-6DDFB4BB-5F42-4264-9553-908892634A77Q28376863-CAE0EC83-A2ED-48BD-87B6-919A90CF6BAAQ38187134-B8014BE0-1DD1-4A58-9699-10C435CCBC14Q38835410-F037D10B-0A00-41E4-BC68-E6784B2F3C88Q42753252-AF40FC41-6EA8-4810-B0DF-9CA00F386E93Q47683869-3CDC2F6D-B738-4005-B0B2-39603E9D7C03Q50562505-D19395AE-0EF4-4DDC-89D8-79187CA8619EQ50782611-8E3C8C1C-7C46-4763-80BE-FDA8C884E118Q51887755-C7BC2BB0-EC86-42F5-B312-29089DE634ACQ56334046-84EDC98A-9207-456C-9B62-789E252BC8FCQ56447341-68106440-0998-47BE-8B5F-AA28C8825C52Q56762690-50F726F0-CDBE-432F-B3F7-85A886ADD439Q56762874-C4A8E67E-CD6A-4E5F-993E-C171B40FFE9FQ56763184-EEB4B838-58AB-4241-BC6E-16C68EC2482CQ56769406-06005426-76E5-4CBE-B3E6-13DA84E87628Q56769619-82E42B42-A199-4C8F-9259-C454B27B4065Q56775003-5328416D-3D51-409E-ABF4-66BFD5D57541Q56894755-76E6C2DA-F171-43E8-BF7E-6796B8DFDD99Q56896589-A4103EB5-3BAD-48A3-A063-4D4BC9988FFCQ56897834-634B376E-548D-4ED3-AE85-C5F4AF605BFAQ56898098-F69D8972-68E7-41FA-93CD-D6D428265467Q56916618-25CD6A3C-66E2-4B7F-B4C1-D10DBACC5B5FQ56920198-B4865727-735F-4929-BAC1-D6AFB24E332DQ57102987-9DBC474D-BB4C-4920-8500-B31F243DB972Q57103690-F4058F46-E036-40E1-A8CE-04437DF82B8BQ57117982-47B78C7D-3006-43B5-9426-8D4F0FA61CC1Q57123604-B8593758-056D-4C7E-B270-DEC2A60B6988Q57124454-BEF5F5E6-DB86-48CE-8B7D-4C3778FCBC65
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift
@nl
wissenschaftliche Fachzeitschrift
@de
name
Prescrire international
@ast
Prescrire international
@en
Prescrire international
@es
Prescrire international
@it
Prescrire international
@nl
type
label
Prescrire international
@ast
Prescrire international
@en
Prescrire international
@es
Prescrire international
@it
Prescrire international
@nl
altLabel
Prescrire Int
@en
prefLabel
Prescrire international
@ast
Prescrire international
@en
Prescrire international
@es
Prescrire international
@it
Prescrire international
@nl
P1055
P1156
P1277
P1476
Prescrire international
@en